Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study.

Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS.

Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23.

PMID:
31015198
2.

Genetic counseling referral for ovarian cancer patients: a call to action.

Garcia C, Harrison K, Ring KL, Sullivan MW, Rauh LA, Modesitt SC.

Fam Cancer. 2019 Jul;18(3):303-309. doi: 10.1007/s10689-019-00129-5.

PMID:
30993488
3.

Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.

Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.

Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.

4.

Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?

Thomas MH, Higgs LK, Modesitt SC, Schroen AT, Ring KL, Dillon PM.

J Genet Couns. 2019 Jun;28(3):700-707. doi: 10.1002/jgc4.1044. Epub 2019 Feb 1.

PMID:
30706980
5.

Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.

Sullivan MW, Camacho FT, Mills AM, Modesitt SC.

Gynecol Oncol. 2019 Jan;152(1):119-126. doi: 10.1016/j.ygyno.2018.10.029. Epub 2018 Oct 28.

PMID:
30376964
6.

Enhanced recovery program for minimally invasive and vaginal urogynecologic surgery.

Trowbridge ER, Evans SL, Sarosiek BM, Modesitt SC, Redick DL, Tiouririne M, Thiele RH, Hedrick TL, Hullfish KL.

Int Urogynecol J. 2019 Feb;30(2):313-321. doi: 10.1007/s00192-018-3794-0. Epub 2018 Oct 29.

PMID:
30374533
7.

Intussusception as a rare cause of bowel obstruction in a woman with recurrent ovarian cancer.

Sullivan MW, Modesitt SC.

Gynecol Oncol Rep. 2018 Aug 11;26:4-6. doi: 10.1016/j.gore.2018.08.002. eCollection 2018 Nov.

8.

Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it.

Staples JN, Rauh L, Peach MS, Baker WD, Modesitt SC.

Gynecol Oncol Rep. 2018 Apr 24;25:30-34. doi: 10.1016/j.gore.2018.04.009. eCollection 2018 Aug.

9.

Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.

Meiss AE, Thomas M, Modesitt SC, Ring KL, Atkins KA, Mills AM.

Hum Pathol. 2018 Dec;82:20-31. doi: 10.1016/j.humpath.2018.06.024. Epub 2018 Jun 26.

PMID:
29958926
10.

Vaginal sarcoidosis without other organ involvement in a patient with a history of endometrial cancer: A case report.

Knisely AT, Girton MR, Hintz HC, Modesitt SC.

Gynecol Oncol Rep. 2018 Jan 10;23:34-36. doi: 10.1016/j.gore.2018.01.004. eCollection 2018 Feb.

11.

Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L.

Gynecol Oncol. 2018 Jul;150(1):119-126. doi: 10.1016/j.ygyno.2018.05.017. Epub 2018 May 18.

PMID:
29778506
12.

Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.

Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC, Ring KL.

Mod Pathol. 2018 Aug;31(8):1282-1290. doi: 10.1038/s41379-018-0039-1. Epub 2018 Mar 20.

13.

Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).

Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Wallace K, Schildkraut JM.

Int J Gynecol Pathol. 2019 Mar;38(2):157-170. doi: 10.1097/PGP.0000000000000494.

PMID:
29485423
14.

Analysis of the circular RNA transcriptome in endometrial cancer.

Chen BJ, Byrne FL, Takenaka K, Modesitt SC, Olzomer EM, Mills JD, Farrell R, Hoehn KL, Janitz M.

Oncotarget. 2017 Dec 20;9(5):5786-5796. doi: 10.18632/oncotarget.23534. eCollection 2018 Jan 19.

15.

Hereditary Cancers in Gynecology: What Physicians Should Know About Genetic Testing, Screening, and Risk Reduction.

Ring KL, Modesitt SC.

Obstet Gynecol Clin North Am. 2018 Mar;45(1):155-173. doi: 10.1016/j.ogc.2017.10.011. Review.

PMID:
29428283
16.

Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer.

Chen BJ, Byrne FL, Takenaka K, Modesitt SC, Olzomer EM, Mills JD, Farrell R, Hoehn KL, Janitz M.

Gynecol Oncol. 2017 Dec;147(3):654-662. doi: 10.1016/j.ygyno.2017.10.006. Epub 2017 Oct 17.

PMID:
29050779
17.

The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis.

Turner TB, Dilley SE, Smith HJ, Huh WK, Modesitt SC, Rose SL, Rice LW, Fowler JM, Straughn JM Jr.

Gynecol Oncol. 2017 Sep;146(3):642-646. doi: 10.1016/j.ygyno.2017.06.026. Epub 2017 Jun 24.

PMID:
28655413
18.

Current and future role of genetic screening in gynecologic malignancies.

Ring KL, Garcia C, Thomas MH, Modesitt SC.

Am J Obstet Gynecol. 2017 Nov;217(5):512-521. doi: 10.1016/j.ajog.2017.04.011. Epub 2017 Apr 12. Review.

PMID:
28411145
19.

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.

Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM.

Am J Surg Pathol. 2017 Mar;41(3):326-333. doi: 10.1097/PAS.0000000000000783.

PMID:
27984238
20.

The emerging role of long non-coding RNAs in endometrial cancer.

Takenaka K, Chen BJ, Modesitt SC, Byrne FL, Hoehn KL, Janitz M.

Cancer Genet. 2016 Oct;209(10):445-455. doi: 10.1016/j.cancergen.2016.09.005. Epub 2016 Sep 13. Review.

PMID:
27810073
21.
22.

Enhanced Recovery Implementation in Major Gynecologic Surgeries: Effect of Care Standardization.

Modesitt SC, Sarosiek BM, Trowbridge ER, Redick DL, Shah PM, Thiele RH, Tiouririne M, Hedrick TL.

Obstet Gynecol. 2016 Sep;128(3):457-66. doi: 10.1097/AOG.0000000000001555.

PMID:
27500337
23.

Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.

Secord AA, Hasselblad V, Von Gruenigen VE, Gehrig PA, Modesitt SC, Bae-Jump V, Havrilesky LJ.

Gynecol Oncol. 2016 Jan;140(1):184-90. doi: 10.1016/j.ygyno.2015.10.020. Epub 2015 Oct 31. Review.

PMID:
26524722
24.

Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.

Mills AM, Sloan EA, Thomas M, Modesitt SC, Stoler MH, Atkins KA, Moskaluk CA.

Am J Surg Pathol. 2016 Feb;40(2):155-65. doi: 10.1097/PAS.0000000000000544.

PMID:
26523542
25.

Women at extreme risk for obesity-related carcinogenesis: Baseline endometrial pathology and impact of bariatric surgery on weight, metabolic profiles and quality of life.

Modesitt SC, Hallowell PT, Slack-Davis JK, Michalek RD, Atkins KA, Kelley SL, Arapovic S, Shupnik MA, Hoehn K.

Gynecol Oncol. 2015 Aug;138(2):238-45. doi: 10.1016/j.ygyno.2015.05.015. Epub 2015 May 23.

PMID:
26013696
26.

Serous tubal intraepithelial carcinoma: an incidental finding at the time of prophylactic bilateral salpingo-oophorectomy.

Vaughan MH, Modesitt SC, Mo Y, Trowbridge ER.

Case Rep Obstet Gynecol. 2015;2015:760429. doi: 10.1155/2015/760429. Epub 2015 Feb 23.

27.

What is new in endometrial hyperplasia treatment or prevention? Best articles from the past year.

Modesitt SC.

Obstet Gynecol. 2014 Nov;124(5):1029-30. doi: 10.1097/AOG.0000000000000530.

PMID:
25437732
28.

Metabolic vulnerabilities in endometrial cancer.

Byrne FL, Poon IK, Modesitt SC, Tomsig JL, Chow JD, Healy ME, Baker WD, Atkins KA, Lancaster JM, Marchion DC, Moley KH, Ravichandran KS, Slack-Davis JK, Hoehn KL.

Cancer Res. 2014 Oct 15;74(20):5832-45. doi: 10.1158/0008-5472.CAN-14-0254. Epub 2014 Sep 9.

29.

Perceptions of obesity and cancer risk in female bariatric surgery candidates: highlighting the need for physician action for unsuspectingly obese and high risk patients.

Henretta MS, Copeland AR, Kelley SL, Hallowell PT, Modesitt SC.

Gynecol Oncol. 2014 Apr;133(1):73-7. doi: 10.1016/j.ygyno.2014.01.016.

PMID:
24680594
30.

Desmoplastic small round cell tumor of the ovary: A rare but devastating disease in young women.

Nakayama J, Nassau S, Atkins K, Modesitt SC.

Gynecol Oncol Case Rep. 2013 Feb 26;7:16-8. doi: 10.1016/j.gynor.2013.02.006. eCollection 2014 Jan.

31.

Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era.

Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, Jazaeri AA, Cantrell LA, Duska LR.

Gynecol Oncol Case Rep. 2013 Feb 11;5:6-9. doi: 10.1016/j.gynor.2013.02.002. eCollection 2013.

32.

In reply.

Modesitt SC.

Obstet Gynecol. 2013 Aug;122(2 Pt 1):394. doi: 10.1097/AOG.0b013e31829bd8b5. No abstract available.

PMID:
23969814
33.

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A.

Mol Cancer Ther. 2013 Oct;12(10):1958-67. doi: 10.1158/1535-7163.MCT-12-1028. Epub 2013 Aug 12.

34.

What is new in gynecologic oncology?: thought-provoking articles from the past year.

Modesitt SC.

Obstet Gynecol. 2013 Apr;121(4):872-3. doi: 10.1097/AOG.0b013e31828ac8e9.

PMID:
23635689
35.

Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.

Ring KL, Connor EV, Atkins KA, Ricketts W, Kashlan B, Modesitt SC.

Int J Gynecol Cancer. 2013 Jun;23(5):853-60. doi: 10.1097/IGC.0b013e31828eed9c.

PMID:
23552806
36.

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK.

Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13.

37.

Post Approval Human Papillomavirus Vaccine Uptake Is Higher in Minorities Compared to Whites in Girls Presenting for Well-Child Care.

Pierce JY, Korte JE, Carr LA, Gasper CB, Modesitt SC.

Vaccines (Basel). 2013 Jul 17;1(3):250-61. doi: 10.3390/vaccines1030250.

38.

Missed opportunities for primary endometrial cancer prevention: how to optimize early identification and treatment of high-risk women.

Modesitt SC.

Obstet Gynecol. 2012 Nov;120(5):989-91. doi: http://10.1097/AOG.0b013e31827237ef. No abstract available.

PMID:
23090512
39.

Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia.

Giugale LE, Di Santo N, Smolkin ME, Havrilesky LJ, Modesitt SC.

Gynecol Oncol. 2012 Nov;127(2):326-31. doi: 10.1016/j.ygyno.2012.08.014. Epub 2012 Aug 19.

PMID:
22910692
40.

Hyperandrogenism of ovarian etiology: utilizing differential venous sampling for diagnosis.

Bailey AP, Schutt AK, Carey RM, Angle JF, Modesitt SC.

Obstet Gynecol. 2012 Aug;120(2 Pt 2):476-9. doi: 10.1097/AOG.0b013e31825a711c.

PMID:
22825271
41.

Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer.

Modesitt SC, Hsu JY, Chowbina SR, Lawrence RT, Hoehn KL.

Int J Gynecol Cancer. 2012 Jun;22(5):732-41. doi: 10.1097/IGC.0b013e3182510496.

PMID:
22635025
42.

Frailty: an outcome predictor for elderly gynecologic oncology patients.

Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA.

Gynecol Oncol. 2012 Jul;126(1):20-4. doi: 10.1016/j.ygyno.2012.04.019. Epub 2012 Apr 19.

PMID:
22522190
43.

Coexisting atypical polypoid adenomyoma and endometrioid endometrial carcinoma in a young woman with Cowden Syndrome: Case report and implications for screening and prevention.

Edwards JM, Alsop S, Modesitt SC.

Gynecol Oncol Case Rep. 2012 Jan 5;2(2):29-31. doi: 10.1016/j.gynor.2011.12.004. eCollection 2012.

44.

Morbidly obese women with and without endometrial cancer: are there differences in measured physical fitness, body composition, or hormones?

Modesitt SC, Geffel DL, Via J, L Weltman A.

Gynecol Oncol. 2012 Mar;124(3):431-6. doi: 10.1016/j.ygyno.2011.11.013. Epub 2011 Nov 18.

PMID:
22101155
45.
46.

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK.

Lancet Oncol. 2011 Nov;12(12):1109-17. doi: 10.1016/S1470-2045(11)70244-3. Epub 2011 Oct 10.

47.

Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma.

Convery PA, Cantrell LA, Di Santo N, Broadwater G, Modesitt SC, Secord AA, Havrilesky LJ.

Gynecol Oncol. 2011 Oct;123(1):65-70. doi: 10.1016/j.ygyno.2011.06.025. Epub 2011 Jul 13.

PMID:
21742369
48.

Hormone replacement therapy in gynecologic cancer survivors: why not?

Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN.

Gynecol Oncol. 2011 Aug;122(2):447-54. doi: 10.1016/j.ygyno.2011.03.012. Epub 2011 Apr 6. Review.

PMID:
21474167
49.

A nomogram for estimating the probability of ovarian cancer.

Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ.

Gynecol Oncol. 2011 Apr;121(1):2-7. doi: 10.1016/j.ygyno.2010.12.365. Epub 2011 Jan 26.

PMID:
21269667
50.

Appendiceal pathology at the time of oophorectomy for ovarian neoplasms.

Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, Jazaeri AA.

Obstet Gynecol. 2010 Dec;116(6):1348-53. doi: 10.1097/AOG.0b013e3181fae628.

PMID:
21099601

Supplemental Content

Loading ...
Support Center